RxDoctor Payments Data

Vernon Carriere, MD

Gastroenterology · Metairie, LANPI 1619180734

Payments from drug & device makers

$13,066in general payments, 2019–2025

Across 883 payments — averaging $14.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Johnson & Johnson$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$749
  • Bristol Myers Squibb$700
  • Pfizer$525
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$12,90599%
  • Education$1611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,066 in reported general payments places this provider in the 75th percentile of 254 gastroenterology providers in Louisiana.

See all gastroenterology providers in Louisiana

Medicare billing

Part B allowed, 2024
$158,368
Medicare patients
416
Services billed
3,521

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide261$167,914
ClenpiqSod Picosulf/Mag Ox/Citric Ac326$53,470
CreonLipase/Protease/Amylase13$48,370
ViberziEluxadoline11$16,762
Mesalamine16$7,134
Pantoprazole Sodium556$5,529
Cholestyramine LightCholestyramine57$4,307
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag11$1,381
Budesonide DrBudesonide12$1,349
Ondansetron OdtOndansetron70$1,082
Dicyclomine Hcl95$973
CholestyramineCholestyramine (With Sugar)11$855
Azathioprine16$802
Sucralfate17$734
Omeprazole92$512

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon, Viberzi$3,997$233,045285 claims
Ferring Pharmaceuticals Inc.Clenpiq$41$53,470326 claims
Braintree Laboratories, Inc.Suflave$67$1,38111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 254 gastroenterology providers in Louisiana.

Other gastroenterology in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →